Skip to main content
Signal8
Launch Terminal

Regencell Bioscience Holdings Ltd (RGC)

Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.

Sector: Medicinal Chemicals & Botanical Products

Industry: Drug Manufacturers - Specialty & Generic

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited

NASDAQ:RGCHealthcare
-11.86%$6.76
AH Close$6.71-0.77%vs close
Mkt Cap$3.35B
Float17.8M
O/S495.88M
Inst Own0.3%
SI2.5%
Dilution
Regencell Bioscience Holdings Limited logoNASDAQ:RGC$6.76-11.86%
FormDescription
20-F
ANNUAL REPORT
6
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
6-K
REPORT OF FOREIGN PRIVATE ISSUER
2
424B5
PROSPECTUS SUPPLEMENT
6-K
REPORT OF FOREIGN PRIVATE ISSUER
6-K
REPORT OF FOREIGN PRIVATE ISSUER
6-K
REPORT OF FOREIGN PRIVATE ISSUER
6-K
REPORT OF FOREIGN PRIVATE ISSUER
6-K
REPORT OF FOREIGN PRIVATE ISSUER
6-K
REPORT OF FOREIGN PRIVATE ISSUER
424B5
PROSPECTUS SUPPLEMENT
F-3ASR
REGISTRATION STATEMENT
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
6-K
REPORT OF FOREIGN PRIVATE ISSUER
20-F
ANNUAL REPORT
13D/A
Beneficial Ownership Report (Active, Amended)
6-K
REPORT OF FOREIGN PRIVATE ISSUER
6-K
REPORT OF FOREIGN PRIVATE ISSUER

1-25 of 85